In a secret meeting MHRA recently voted to remove a drug which causes heart attacks in the UK. But their decision was never made public – and its instructions are being ignored by British drug giant GlaxoSmithKline.
Panorama last night revealed that Avandia, a drug which costs 20 times as much as older diabetes treatment, doubles the risk of heart failure. Yet not only did GSK continue to sell the drug, they also appeared anxious to avoid any discussion or scrutiny.
“Frankly, the last thing we want to do is get into a public debate,” GSK chief medical officer was taped as saying.
Previously, the MHRA has accepted GSK studies on trust. However, US regulators found that the GSK had manipulated studies to obtain the results they wanted.
The company also suppressed studies that were not in its favour, stating in an internal email:
“These put Avandia in quite a negative light… we would hope these do not see the light of day.”
The programme also found that doctors who wrote the most favourable reviews of Avandia had been paid by GSK.
Pharmaceutical Companies and the E-Cigarette
Many e-cigarette users believe that pharmaceutical companies are behind a campaign to remove the e-cigarette.
Electronic cigarettes threaten the smoking cessation industry run by the pharmaceutical companies, as highlighted by an industry report which has been removed from the net since we highlighted it.
On our website we highlight some of the funds and grants made by pharmaceutical companies to anti-smoking groups who oppose the e-cigarette despite the backing from tobacco harm reduction scientists.